CHRS Q1 2019 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$219M

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$37M

Gross Profit

$35M94.0% margin

Operating Income

-$17M-44.7% margin

Net Income

-$20M-53.9% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$57M

Free Cash Flow

-$57M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$186M

Total Liabilities

$225M

Stockholders' Equity

-$39M

Cash & Equivalents

$82M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37M	$0	—
Gross Profit	$35M	-$25M	+237.0%
Operating Income	-$17M	-$42M	+60.5%
Net Income	-$20M	-$44M	+54.8%